[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA200700756A1 - Пиримидоны - Google Patents

Пиримидоны

Info

Publication number
EA200700756A1
EA200700756A1 EA200700756A EA200700756A EA200700756A1 EA 200700756 A1 EA200700756 A1 EA 200700756A1 EA 200700756 A EA200700756 A EA 200700756A EA 200700756 A EA200700756 A EA 200700756A EA 200700756 A1 EA200700756 A1 EA 200700756A1
Authority
EA
Eurasian Patent Office
Prior art keywords
integer
formula
disease
halogen
pirimidony
Prior art date
Application number
EA200700756A
Other languages
English (en)
Other versions
EA013004B1 (ru
Inventor
Казутоси Ватанабе
Кендзи Фукунага
Тосиюки Кохара
Фумиаки Уехара
Синсуке Хики
Сатоси Йокосима
Original Assignee
Мицубиси Фарма Корпорейшн
Санофи-Авентис
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мицубиси Фарма Корпорейшн, Санофи-Авентис filed Critical Мицубиси Фарма Корпорейшн
Publication of EA200700756A1 publication Critical patent/EA200700756A1/ru
Publication of EA013004B1 publication Critical patent/EA013004B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Описываются соединения, представленные формулой (I), их оптически активные изомеры или их фармацевтически приемлемые соли, где в указанной формуле Rпредставляет (C-C)алкил; Rпредставляет атом водорода или подобное; Rпредставляет галоген или подобное; q равен целому числу от 1 до 7; Rпредставляет галоген или подобное; р равен 0 или целому числу от 1 до 5; Rпредставляет (С-С)арил, гетероцикл или подобное; и Х представляет кислород, NH или подобное, которые применяют для профилактики и/или лечения заболевания, вызванного гиперактивностью тау-протеинкиназы 1, такого как нейродегенеративные заболевания (например, болезнь Альцгеймера).
EA200700756A 2004-09-29 2005-09-29 Производные 6-пиридинил-4-пиримидона в качестве ингибиторов тау-протеинкиназы 1 EA013004B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004313115 2004-09-29
PCT/JP2005/018497 WO2006036015A2 (en) 2004-09-29 2005-09-29 6- (pyridinyl) -4-pyrimidone derivates as tau protein kinase 1 inhibitors

Publications (2)

Publication Number Publication Date
EA200700756A1 true EA200700756A1 (ru) 2007-10-26
EA013004B1 EA013004B1 (ru) 2010-02-26

Family

ID=35848411

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200700756A EA013004B1 (ru) 2004-09-29 2005-09-29 Производные 6-пиридинил-4-пиримидона в качестве ингибиторов тау-протеинкиназы 1

Country Status (25)

Country Link
US (1) US8129377B2 (ru)
EP (3) EP2261224A3 (ru)
JP (1) JP5186213B2 (ru)
KR (1) KR20070057931A (ru)
CN (1) CN101048397A (ru)
AR (1) AR051823A1 (ru)
AT (1) ATE499356T1 (ru)
AU (1) AU2005288045B2 (ru)
BR (1) BRPI0515851A (ru)
CA (1) CA2581179A1 (ru)
CY (1) CY1112326T1 (ru)
DE (1) DE602005026546D1 (ru)
DK (1) DK1805164T3 (ru)
EA (1) EA013004B1 (ru)
ES (1) ES2359071T3 (ru)
IL (1) IL182223A0 (ru)
MX (1) MX2007003722A (ru)
NO (1) NO20072214L (ru)
NZ (1) NZ554722A (ru)
PL (1) PL1805164T3 (ru)
PT (1) PT1805164E (ru)
SI (1) SI1805164T1 (ru)
TW (1) TWI354669B (ru)
WO (1) WO2006036015A2 (ru)
ZA (1) ZA200703383B (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR050865A1 (es) * 2004-09-09 2006-11-29 Sanofi Aventis Derivados de 2- morfolino-4-pirimidona
GB0510142D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
GB0510141D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
TW200740779A (en) 2005-07-22 2007-11-01 Mitsubishi Pharma Corp Intermediate compound for synthesizing pharmaceutical agent and production method thereof
TW200813015A (en) * 2006-03-15 2008-03-16 Mitsubishi Pharma Corp 2-(cyclic amino)-pyrimidone derivatives
CN101528729A (zh) * 2006-08-23 2009-09-09 辉瑞产品公司 作为gsk-3抑制剂的嘧啶酮化合物
WO2008026046A1 (en) * 2006-08-30 2008-03-06 Pfizer Products Inc. Morpholine d3 dopamine antagonists
AR064660A1 (es) 2006-12-26 2009-04-15 Mitsubishi Tanabe Pharma Corp Derivados de pirimidinona 6-heterociclica 2-sustituida, medicamentos que los contienen y usos para prevenir y/o tratar enfermedades neurodegenerativas entre otras
AU2008290329B2 (en) 2007-08-22 2011-12-22 Astrazeneca Ab Cyclopropyl amide derivatives
US8198437B2 (en) 2007-09-14 2012-06-12 Mitsubishi Tanabe Pharma Corporation 6-pyrimidinyl-pyrimid-4-one derivative
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
JP5535310B2 (ja) 2009-08-13 2014-07-02 田辺三菱製薬株式会社 タウプロテインキナーゼ１阻害剤としてのピリミドン誘導体
JPWO2011062194A1 (ja) 2009-11-18 2013-04-04 武田薬品工業株式会社 アミノピリジン誘導体
US9452980B2 (en) * 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
AU2011218491C1 (en) 2010-02-18 2015-05-14 Astrazeneca Ab Processes for making cyclopropyl amide derivatives and intermediates associated therewith
EP2568812B1 (en) * 2010-05-11 2016-10-26 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
EP2928473B1 (en) 2012-12-07 2017-06-28 Merck Sharp & Dohme Corp. Regioselective n-2 arylation of indazoles
JP7179014B2 (ja) 2017-04-24 2022-11-28 テサロ， インコーポレイテッド ニラパリブの製造方法
CN117143079A (zh) * 2018-11-06 2023-12-01 上海奕拓医药科技有限责任公司 一种螺芳环化合物及其应用
CN111704611B (zh) * 2019-07-25 2022-01-14 上海凌达生物医药有限公司 一类芳基螺环类shp2抑制剂化合物、制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR023052A1 (es) * 1998-09-25 2002-09-04 Mitsuharu Yoshimura Milton Derivados de pirimidona
EP1136483A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-[Piperazinyl]pyrimidone derivatives
EP1136482A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors
KR100754596B1 (ko) 2001-09-21 2007-09-05 미쯔비시 웰 파마 가부시키가이샤 3-치환-4-피리미돈 유도체
AU2002337499B2 (en) * 2001-09-21 2007-08-23 Mitsubishi Pharma Corporation 3-substituted-4-pyrimidone derivatives
EP1454908B1 (en) * 2003-03-07 2008-02-27 Sanofi-Aventis Substituted pyridinyl-2-(diaza-bicyclo-alkyl)-pyrimidinone derivatives
TWI357408B (en) 2003-03-26 2012-02-01 Mitsubishi Tanabe Pharma Corp 3-substituted-4-pyrimidone derivatives

Also Published As

Publication number Publication date
CA2581179A1 (en) 2006-04-06
EP2266969A3 (en) 2011-02-16
AU2005288045A1 (en) 2006-04-06
AR051823A1 (es) 2007-02-14
SI1805164T1 (sl) 2011-05-31
EP1805164B1 (en) 2011-02-23
ATE499356T1 (de) 2011-03-15
BRPI0515851A (pt) 2008-08-12
JP5186213B2 (ja) 2013-04-17
DE602005026546D1 (de) 2011-04-07
WO2006036015A3 (en) 2006-06-01
EP1805164B9 (en) 2011-09-07
PT1805164E (pt) 2011-04-11
NZ554722A (en) 2010-07-30
TWI354669B (en) 2011-12-21
EP1805164A2 (en) 2007-07-11
IL182223A0 (en) 2007-09-20
PL1805164T3 (pl) 2011-07-29
ZA200703383B (en) 2009-05-27
EA013004B1 (ru) 2010-02-26
CN101048397A (zh) 2007-10-03
US8129377B2 (en) 2012-03-06
EP2261224A2 (en) 2010-12-15
EP2266969A2 (en) 2010-12-29
EP2261224A3 (en) 2011-02-16
US20090239864A1 (en) 2009-09-24
AU2005288045B2 (en) 2011-08-18
KR20070057931A (ko) 2007-06-07
DK1805164T3 (da) 2011-05-16
TW200626573A (en) 2006-08-01
WO2006036015A2 (en) 2006-04-06
MX2007003722A (es) 2007-05-23
AU2005288045A2 (en) 2008-05-29
NO20072214L (no) 2007-06-12
JP2008514587A (ja) 2008-05-08
ES2359071T3 (es) 2011-05-18
CY1112326T1 (el) 2015-12-09

Similar Documents

Publication Publication Date Title
EA200700756A1 (ru) Пиримидоны
EA200870358A1 (ru) 2-(циклический амино) пиримидоновые производные в качестве ингибиторов tpk1
NO20071787L (no) 2-morfolin-4-pyrimidonforbindelse
NO20064726L (no) Imidazolforbindelser for behandling av neurodegenerative forstyrrelser
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
MX2007006896A (es) Fenil-metanonas bi- y triciclicas sustituidas como inhibidores del transportador 1 de glicina (glyt-1) para el tratamiento de la enfermedad de alzheimer.
NO20070606L (no) Inhibitorer av IAP
TW200635585A (en) Monocyclic substituted methanones
EA200970637A1 (ru) 2-замещенные-6-гетероциклилпроизводные пиримидона в качестве ингибиторов тау-протеинкиназы
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
DE602004028150D1 (de) Aminopyrazolderivate als gsk-3-inhibitoren
EA200401114A2 (ru) Замещённые гидроксиэтиламины
EA200701780A1 (ru) Противоопухолевое средство
EA201070366A1 (ru) 3-метил-2-((2s)-2-(4-(3-метил-1,2,4-оксадиазол-5-ил)фенил)морфолино)-6-(пиримидин-4-ил)пиримидин-4(3н)-он в качестве ингибитора тау-протеинкиназы
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
EA200501311A1 (ru) ПРОИЗВОДНЫЕ ЗАМЕЩЁННОГО 8-ПЕРФТОРАЛКИЛ-6,7,8,9-ТЕТРАГИДРОПИРИМИДО[1,2-a]ПИРИМИДИН-4-ОНА
ATE409480T1 (de) Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren
EA201070367A1 (ru) Производное 6-пиримидинилпиримид-4-она
DE602006014022D1 (de) 5-substituierte indol-2-carbonsäureamidderivate
EA200600760A1 (ru) Новые соединения фенилпиридилпиперазина, способ их получения и фармацевтические композиции, содержащие их
ATE524171T1 (de) Verwendung von 2-(2-nitro-4- trifluormethylbenzoyl)-1,3-cyclohexandion bei der behandlung der parkinson-krankheit
WO2006055434A3 (en) Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease
NO20073330L (no) Sulfanylsubstituerte fenylmetanoner som glycintransportor 1 (glyt-1) inhibitorer for behandling av nevrologiske og nevropsykiatriske forstyrrelser
ATE391122T1 (de) 4 ((2,4-dichloro-5-methoxyphenyl)amino)-6-alkoxy- 7-ethynyl-3-quinolinecarbonitrile zur behandlung von ischämie
TH96043A (th) สารประกอบไพริมิโดน

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU